Exelixis, Inc. - Common Stock (NQ:EXEL)

58.34 -0.05 (-0.09%)

Delayed Quote Updated: 9:57 AM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Exelixis, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

23 24 Next >

Whirlpool Posts Downbeat Earnings, Joins Harmonic, Stanley Black & Decker And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗

July 29, 2025

Via Benzinga

Exelixis Q2 Revenue Falls 11 Percent ↗

July 28, 2025

Via The Motley Fool

Topics Earnings Intellectual Property

12 Health Care Stocks Moving In Monday's After-Market Session ↗

July 28, 2025

Via Benzinga

Curious about the stocks that are showing activity after the closing bell on Monday? ↗

July 28, 2025

After the closing bell on Monday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session.

Via Chartmill

Peering Into Exelixis's Recent Short Interest ↗

July 22, 2025

Via Benzinga

Peering Into Exelixis's Recent Short Interest ↗

July 04, 2025

Via Benzinga

Exelixis Announces Second Quarter 2025 Financial Results and Provides Corporate Update

July 28, 2025

From Exelixis, Inc.

Via Business Wire

EXELIXIS INC (NASDAQ:EXEL): A Prime Example of Affordable Growth in Biotech ↗

July 28, 2025

EXELIXIS (NASDAQ:EXEL) offers strong growth, fair valuation, and financial health, fitting the "Affordable Growth" strategy with high scores in profitability and low bankruptcy risk.

Via Chartmill

Topics Bankruptcy

Uncovering Potential: Exelixis's Earnings Preview ↗

July 25, 2025

Via Benzinga

EXELIXIS INC (NASDAQ:EXEL): A Strong Growth Stock with Bullish Technical Breakout Potential ↗

July 25, 2025

EXELIXIS INC (EXEL) combines strong growth fundamentals—high profitability, solid financials, and rising revenue—with bullish technical signals, making it a promising breakout candidate for investors.

Via Chartmill

Exelixis’ Partner Ipsen Receives European Commission Approval for CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors

July 24, 2025

From Exelixis, Inc.

Via Business Wire

Earnings Scheduled For July 28, 2025 ↗

July 28, 2025

Via Benzinga

EXELIXIS INC (NASDAQ:EXEL) – A High-Growth Momentum Stock with Strong Technical Setup ↗

July 22, 2025

EXELIXIS INC (NASDAQ:EXEL) shows strong earnings momentum, expanding margins, and a high technical rating, making it a candidate for growth investors and breakout traders.

Via Chartmill

Here's Why This $50 Healthcare Stock Could Be the Next $200 Winner ↗

July 20, 2025

Via The Motley Fool

EXELIXIS INC (NASDAQ:EXEL) – A Strong Contender in High-Growth Oncology Stocks ↗

July 19, 2025

EXELIXIS (NASDAQ:EXEL) shows strong technical and fundamental growth, meeting Minervini’s Trend Template criteria with high earnings momentum and a bullish chart setup.

Via Chartmill

After Falling 68%, Where Will This Weight-Loss Drug Stock Be in 2 Years? History Shows Massive Gains Ahead. ↗

July 19, 2025

Yet another biopharma name has been run through a familiar trading cycle that often ends on a bullish note.

Via The Motley Fool

Topics Intellectual Property

Exelixis to Release Second Quarter 2025 Financial Results on Monday, July 28, 2025

July 14, 2025

From Exelixis, Inc.

Via Business Wire

Assessing Exelixis: Insights From 12 Financial Analysts ↗

July 10, 2025

Via Benzinga

EXELIXIS INC (NASDAQ:EXEL) – A Strong Contender for Growth Investors ↗

July 08, 2025

EXELIXIS INC (NASDAQ:EXEL) shows strong growth, profitability, and financial health, making it a standout for investors following Louis Navellier’s strategy. With high earnings surprises and...

Via Chartmill

EXELIXIS INC (NASDAQ:EXEL) – A Strong Growth Stock with Attractive Valuation ↗

July 05, 2025

EXELIXIS INC (NASDAQ:EXEL) offers strong growth potential at a reasonable valuation, backed by solid profitability and a debt-free balance sheet. A compelling pick for growth investors.

Via Chartmill

2 Stocks to Buy With Less Than $50 ↗

July 04, 2025

Via The Motley Fool

Topics Intellectual Property

EXELIXIS INC (NASDAQ:EXEL) - An Undervalued Biotech Stock With Strong Fundamentals ↗

July 02, 2025

EXELIXIS (NASDAQ:EXEL) is an undervalued biotech stock with strong profitability, zero debt, and robust growth prospects, making it a candidate for value investors.

Via Chartmill

EXELIXIS INC (NASDAQ:EXEL) – A Strong Growth Stock with Technical Breakout Potential ↗

June 30, 2025

EXELIXIS (NASDAQ:EXEL) is a strong growth stock with breakout potential, backed by robust earnings, revenue growth, and a healthy technical setup.

Via Chartmill

3 No-Brainer Stocks to Buy for Under $100 Right Now ↗

June 28, 2025

Via The Motley Fool

Topics Intellectual Property

EXELIXIS INC (NASDAQ:EXEL) – A High Growth Momentum Stock with Strong Technical Setup ↗

June 28, 2025

EXELIXIS INC (NASDAQ:EXEL) shows strong earnings momentum, expanding margins, and a high technical rating, making it a candidate for growth investors. The stock is consolidating with clear support...

Via Chartmill

This MakeMyTrip Analyst Turns Bullish; Here Are Top 3 Upgrades For Tuesday ↗

June 24, 2025

Via Benzinga

EXELIXIS INC (NASDAQ:EXEL) – A Strong Contender in Growth and Momentum Investing ↗

June 24, 2025

EXELIXIS INC (NASDAQ:EXEL) shows strong growth momentum and meets Minervini’s trend criteria, making it a stock to watch for high-growth investors.

Via Chartmill

CorMedix Spikes To Four-Year High On A Surprise Deal For Its Leading Drug ↗

June 23, 2025

CorMedix shares bounded to a four-year high Monday after the biotech company inked an expanded deal for its leading drug.

Via Investor's Business Daily

Kroger Posts Better-Than-Expected Earnings, Joins Couchbase, CarMax And Other Big Stocks Moving Higher On Friday ↗

June 23, 2025

Via Benzinga

Exelixis' Zanzalintinib Combo Boosts Survival In Colorectal Cancer, Stock Soars ↗

June 23, 2025

Exelixis' STELLAR-303 trial shows zanzalintinib plus Tecentriq improved survival in colorectal cancer, with no new safety concerns reported.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

23 24 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.